FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 859 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cómo compartir los resultados de las pruebas genéticas con la familia March 22, 2022 Happy 29th Birthday OncoLink! March 7, 2023 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents July 10, 2018 Load more HOT NEWS COVID-19 Vaccines May Be Less Effective in Some People with Cancer Feeding the Gut Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in...
